Nymox Pharmaceutical Corporation (NYMX)
Nymox Pharmaceutical Corporation Revenues: 0.7396M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NYMX Revenues Rankings
| Overall | 2nd percentile | 4343 of 4432 |
| Sector | 9th percentile | 425 of 470 in Healthcare |
| Industry | 23rd percentile | 13 of 17 in Diagnostic Substances |
NYMX Revenues Range, Past 5 Years
| Minimum | 0.0269M | Sep 2010 |
| Maximum | 1.432M | Dec 2011 |
| Average | 0.2818M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these NYMX related companies
NYMX News
Nymox Pharmaceutical (NYMX) Reports Statistically Significant Data for NX-1207 in BPH
May 21, 9:33AM Street Insider
May 21, 9:33AM Street Insider
Nymox NX-1207 Symposium at American Urological Association Annual Meeting May 20 in Atlanta
May 16, 10:15AM GlobeNewswire
May 16, 10:15AM GlobeNewswire
Singular Research Reiterates "Buy" Rating on Nymox With a 12-Month Target Price of $18.00
Apr 30, 11:00AM GlobeNewswire
Apr 30, 11:00AM GlobeNewswire
Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 NX-1207 Trials for BPH
Apr 26, 11:45AM Benzinga
Apr 26, 11:45AM Benzinga
Nymox NX-1207 Symposium at American Urological Association Annual Meeting May 20 in Atlanta
Apr 24, 9:45AM GlobeNewswire
Apr 24, 9:45AM GlobeNewswire
Nymox (NYMX) Reports Strong Data from Follow-Up Assessment of NX-1207 in BPH Patients
Mar 26, 10:02AM Street Insider
Mar 26, 10:02AM Street Insider
Nymox Announces U.S. Phase 2 Clinical Trial of NX-1207 for New Indication - Prostate Cancer
Mar 01, 10:48AM GlobeNewswire
Mar 01, 10:48AM GlobeNewswire
Recordati and Nymox Announce the Start of European Phase III Clinical Trial for NX-1207
Feb 21, 9:30AM Benzinga
Feb 21, 9:30AM Benzinga
Nymox Announces Current Safety Monitoring Committee Results and Update for Phase 3 NX-1207 Trials
Feb 15, 11:20AM Benzinga
Feb 15, 11:20AM Benzinga
Nymox (NYMX) Reports No Significant Safety Concerns from Two Pivotal NX-1207 Phase 3s
Nov 22, 12:03PM Street Insider
Nov 22, 12:03PM Street Insider
Nymox Provides Safety Monitoring Committee Results and Update for Pivotal Phase 3 NX-1207 Trials
Nov 22, 12:01PM GlobeNewswire
Nov 22, 12:01PM GlobeNewswire
Presentation on Nymox NX-1207 Prostate Drug in Orlando Today at American Urological Association Meeting
Nov 04, 12:00PM GlobeNewswire
Nov 04, 12:00PM GlobeNewswire
Long Term Results on Nymox NX-1207 BPH Drug Presented at American Urological Association Meeting in New Orleans
Oct 31, 10:45AM GlobeNewswire
Oct 31, 10:45AM GlobeNewswire
Nymox says data on NX-1207 presented at American Urological Association meeting
Oct 19, 12:57PM FlyOnTheWall
Oct 19, 12:57PM FlyOnTheWall
Nymox Pharma (NYMX) Reports Statistical Significance Achieved on NX-1207 Phase 2 Follow Ups
Oct 19, 12:56PM Street Insider
Oct 19, 12:56PM Street Insider
New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19
Oct 19, 12:54PM GlobeNewswire
Oct 19, 12:54PM GlobeNewswire
Nymox NX-1207 BPH Drug to be Presented at Orlando Meeting of American Urological Association
Oct 11, 10:00AM GlobeNewswire
Oct 11, 10:00AM GlobeNewswire
$NYMX http://chart.ly/nws94w9 macd cross, major level break, volume coming, 8.70ish area next R, good looking chart
about 384 days ago by stockfella
about 384 days ago by stockfella
$NYMX has the momentum people jumping out at the end of the day. Aww. Come down to my order. Little lower.
about 486 days ago by frotuss
about 486 days ago by frotuss
$NYMX http://chart.ly/dpwodur Looks ready to go, look for break of highs
about 500 days ago by markmandy54
about 500 days ago by markmandy54
Correction: RT @Yingwe: $NYMX http://bit.ly/ep8k6W Flagging but still little overBOUGHT.
about 505 days ago by Yingwe
about 505 days ago by Yingwe
$NYMX http://chart.ly/98m7ri9 Flagging but still little oversold. Buy the bottom of the box at 8.06 w/stop under or b/o over 8.63
about 505 days ago by Yingwe
about 505 days ago by Yingwe
$nymx let see if this can test that 7.76 area from 12/17 . nice little move so far
about 521 days ago by danshep55
about 521 days ago by danshep55
$nymx showing a pulse . still under water from my swing entries yest but not that much . 6.44 avg
about 525 days ago by danshep55
about 525 days ago by danshep55
$nymx added more 6.40 im goign to swing this was 7.76 2 days ago . came in light vol . shoud spike shorly
about 526 days ago by danshep55
about 526 days ago by danshep55
$nymx bought 6.47-6.50 rested that big spike now took out yest highs . lets see what it has
about 526 days ago by danshep55
about 526 days ago by danshep55
$nymx on watch next few days. resting after big spike , no position just keeping close eye for next spike
about 527 days ago by danshep55
about 527 days ago by danshep55
Google shows $NYMX as actively searched. http://tinyurl.com/36jl5od
about 531 days ago by whalewisdom
about 531 days ago by whalewisdom
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NYMX | 7.34 | -0.17 | -2.26% | 247.83M |
| NYMT | 6.65 | -0.05 | -0.75% | 93.40M |
| NYH | 13.96 | -0.01 | -0.07% | |
| NTZ | 2.83 | +0.05 | +1.80% | 151.62M |
| NTWK | 0.4649 | -0.03 | -5.12% | 35.08M |
| NTT | 21.29 | -0.06 | -0.28% | 54.04B |
| NTSP | 7.40 | +0.04 | +0.54% | 560.98M |
| NTSC | 5.86 | +0.01 | +0.17% | 66.10M |
| NTRS | 42.85 | -1.09 | -2.48% | 10.60B |
| NTRI | 10.37 | -0.32 | -2.99% | 301.89M |